Towards personalised cancer treatment
The machines used to sequence genes are becoming faster and less expensive to use. Together with colleagues across Norway, including Leonardo Meza-Zepeda (left), Ola Myklebost will be studying every gene in several thousand patients. Credit: Elin Fugelsnes
All types of cancer begin with genetic aberrations in the DNA of normal cells. An extensive research project will examine the errors occurring in the genes of several thousand Norwegian patients. The objective is to develop treatment that is better adapted to the individual patient.
Even though all cancers are caused by gene aberrations (mutations) in the DNA of normal cells, each tumour is unique. Each type of cancer comprises a number of subgroups characterised by different mutations. Since mutation processes are random the mutations that take place in each patient, and even in different cells in the tumour, will differ.
When it comes to treatment, however, most patients are given largely the same regimens. This may be highly effective for some patients while the benefit to others is slight. And some may be so unfortunate as to experience nothing but the side effects.
"One fundamental problem is that the various patient groups have not been categorised adequately. The causes of cancer are far more complicated and complex than we knew," says Ola Myklebost, senior researcher at Oslo University Hospital and professor in the Department of Biosciences at the University of Oslo.
Sequencing every single gene
Professor Myklebost is heading a comprehensive project co-funded under two of the Research Council of Norway's programmes: the Programme for Publicly-initiated Clinical Cancer Studies (KREFT) and the Research Programme on Biotechnology for Innovation (BIOTEK2021).
Using "next generation" gene sequencing, the researchers are first going to examine mutations in all genes in patients suffering from eight different types of cancer: melanoma, breast cancer, colorectal cancer, lymphoma, prostate cancer, sarcoma, leukaemia and myeloma. More studies will be added as the project progresses.
"We want to find out which mutations are distinct in various cancer types and what effect these mutations have. This is an essential starting point for developing and employing personalised treatment far more widely than is the case today," Dr Myklebost says.
Teaming up with Ola Myklebost on the project are researchers and physicians from throughout all the regions of Norway. Initially, the researchers were to sequence 1 000 genes from the blood and tumours of each patient. The plans have since been expanded and the researchers are going to look at all of the roughly 22 000 genes.
"New sequencing machines that are capable of analysing all genes at once at ever increasing speeds are being developed non-stop, and they are becoming less and less expensive to operate. In our work we will be using a machine that is ten times faster than the last one we had. The degree of sequencing we are now planning would simply not be possible with the machine we purchased just three years ago," Professor Myklebost explains.
Laying the foundations for personalised treatment
Numerous studies in recent years have shown that it is wrong to consider one type of cancer as a single, more or less homogeneous illness. For example, the well-known Norwegian cancer researcher Anne-Lise Børresen-Dale and her partners at the Oslo University Hospital have shown that at least ten different kinds of breast cancer exist. It is clear that treatment needs to be adapted to the specific type of cancer as well as to the individual patient.
Professor Myklebost points to lung cancer as a cancer where personalised treatment is being applied.
"Lung cancer researchers are now examining specific mutations in the cancer cell genes that provide a foundation for targeted therapy. A certain mutation found in approximately four per cent of the tumours is responsive to a medicine developed to block this particular pathway. Patients with this type of tumour react well to treatment," the professor explains.
"Unfortunately, there are so many different mutations in the tumour cells that clones arise that do not respond to the medication. These clones eventually gain the upper hand and the effect of the medication diminishes over time," he adds. In some cases second line treatment is available, in others a new mutation profile may reveal more options.
Genetic aberrations across cancer types provide clues
Up to now, the common procedure has been to select medicines and treatment based on the organ affected by cancer. It turns out, however, that many of the same gene aberrations appear across different types of cancer.
This is a very positive finding, Ola Myklebost believes, for instance with regard to rare forms of cancer where the development of disease-specific treatments is not very profitable for the pharmaceutical industry.
"By finding common features between these rare types of cancer and cancers for which medications exist, we may be able to develop new treatment options. One advantage to applying medications already in use for one type of cancer in a new area is that the side-effects are already well known," Professor Myklebost asserts.
Tailoring treatment for each individual patient
The researchers still do not know any single mechanism that is fundamentally responsible for the growth of cancer tumours. As they discover the mechanisms, medications adapted to those specific gene mutations will have to be developed. For the time being, targeted treatments are only available for a handful of patients and at high cost.
There are also many technical, ethical and legal challenges that have to be overcome before personalised treatment becomes a standard part of health services.
"One of the major challenges is documenting the effect of a treatment that is only suitable for a few patients. Classic trials on a large number of randomised patients will of course be impossible," Professor Myklebost points out.
Still, he remains optimistic.
"In coming years diagnostics will steadily improve and become more precise. Gene-sequencing of cancer tumours on a moderate scale may be cost-effective already or will be so in the near future," he concludes.
Provided by The Research Council of Norway
- Researchers find gene that turns up effect of chemotherapy Jan 29, 2013 | not rated yet | 0
- Researchers map the way to personalised treatment for ovarian cancer Nov 17, 2010 | not rated yet | 0
- 'Liquid Biopsy': Blood test gives 'real-time' picture of cancer May 31, 2012 | not rated yet | 0
- Children's brain tumors more diverse than previously believed May 14, 2012 | not rated yet | 0
- BRG1 mutations confer resistance to hormones in lung cancer Mar 15, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 2 hours ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 3 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 3 hours ago | 5 / 5 (2) | 0
A leading expert in childhood cancer at The University of Nottingham is spearheading a Europe-wide lobby of the European Parliament to try to make it easier for doctors to develop and test new treatments on children and young ...
Cancer 4 hours ago | not rated yet | 0
(AP)—Researchers examining the incidence of brain cancer at jet engine manufacturer Pratt & Whitney in Connecticut say they have found no statistically significant elevations in the rate of cancer among workers.
Cancer 5 hours ago | not rated yet | 0
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
7 minutes ago | not rated yet | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
37 minutes ago | not rated yet | 0 |
(HealthDay)—Menopausal hormone therapy should not be used for prevention of coronary heart disease, according to a Committee Opinion from the American College of Obstetricians and Gynecologists (ACOG) published ...
13 minutes ago | not rated yet | 0
The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster ...
36 minutes ago | not rated yet | 0
In Parkinson's disease, the protein "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of the brain become progressively affected as the disease develops and advances. The mechanism underlying this ...
35 minutes ago | not rated yet | 0
After studying noise in one French Quarter neighborhood of New Orleans to determine whether or not noise levels exceeded municipal ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at LSU Health Sciences Center ...
23 minutes ago | not rated yet | 0